MedTrace Logo

Harnessing the Power of Technology: MOMBA for Postpartum Smoking

NCT02237898 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2020-05-21

Study results available
· View outcomes & findings →

Summary

Through a smartphone platform, financial incentives for smoking abstinence in postpartum women can be delivered remotely, thus minimizing the need for participants to come to the office to receive traditional contingency management.

Conditions

  • Smoking Cessation

Interventions

BEHAVIORAL

MoMba Live Long app & Sensordrone™ carbon-monoxide sensor

MoMba Live Long application \& Sensordrone™ carbon-monoxide sensor to deliver contingency management remotely

BEHAVIORAL

Office contingency management

A control group which will receive financial incentives at an in-person office/clinic visit based on expired CO levels obtained through the piCO sensor.

DEVICE

Sensordrone™ carbon-monoxide sensor

A custom breath CO meter built by Sensorcon Inc. (Sensordrone, part No. SDRONEG1) that uses an electrochemical CO gas sensor to measure environmental CO. The Sensordrone is accurate to within 10% with a resolution of 1 parts per million (ppm). The Sensordrone pairs via Bluetooth with the MoMba Live Long application.

DEVICE

MoMba Live Long Smartphone application

The MoMba Live Long app provides an interface for the Sensordrone which allows participants to complete a breath test and see results of smoking status. The app verifies the user is correctly taking the tests by recording pictures using the front facing camera as well as recording audio to verify that the participants where exhaling while taking the test. The app also provided a platform for social interaction based on a previous system where app users can interact with each other and provide support during the quitting process.

Sponsors & Collaborators

  • Yale University

    lead OTHER

  • National Cancer Institute (NCI)

    collaborator NIH

Principal Investigators

  • Megan V Smith, DrPH · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-10
Primary Completion
2019-05-13
Completion
2019-05-13

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02237898 on ClinicalTrials.gov